In the latest quarter, 4 analysts provided ratings for Precision BioSciences (NASDAQ:DTIL), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
4
0
0
0
0
Last 30D
1
0
0
0
0
1M Ago
2
0
0
0
0
2M Ago
1
0
0
0
0
3M Ago
0
0
0
0
0
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $49.75, along with a high estimate of $60.00 and a low estimate of $19.00. Observing a 1558.33% increase, the current average has risen from the previous average price target of $3.00.
Deciphering Analyst Ratings: An In-Depth Analysis
The standing of Precision BioSciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Patrick Trucchio
HC Wainwright & Co.
Maintains
Buy
$60.00
-
Debjit Chattopadhyay
Guggenheim
Announces
Buy
$19.00
-
Patrick Trucchio
HC Wainwright & Co.
Maintains
Buy
$60.00
-
Patrick Trucchio
HC Wainwright & Co.
Adjusts
Buy
$60.00
$3.00
Key Insights:
Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Precision BioSciences. This information provides a snapshot of how analysts perceive ...Full story available on Benzinga.com
Benzinga
